EA201492169A1 - Новые соединения - Google Patents

Новые соединения

Info

Publication number
EA201492169A1
EA201492169A1 EA201492169A EA201492169A EA201492169A1 EA 201492169 A1 EA201492169 A1 EA 201492169A1 EA 201492169 A EA201492169 A EA 201492169A EA 201492169 A EA201492169 A EA 201492169A EA 201492169 A1 EA201492169 A1 EA 201492169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
new connections
diseases
modulation
potential
Prior art date
Application number
EA201492169A
Other languages
English (en)
Other versions
EA025579B1 (ru
Inventor
Джерард М.П. Гиблин
Дэвид Т. Макферсон
Дэвид Р. Витти
Стивен Дж. Стэнвэй
Original Assignee
Конвердженс Фармасьютикалз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Конвердженс Фармасьютикалз Лимитед filed Critical Конвердженс Фармасьютикалз Лимитед
Publication of EA201492169A1 publication Critical patent/EA201492169A1/ru
Publication of EA025579B1 publication Critical patent/EA025579B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Изобретение относится к спиропроизводным, к применению указанных производных для лечения заболеваний и состояний, опосредованных модулированием потенциалзависимых натриевых каналов, к композициям, содержащим указанные производные, и способам их получения.
EA201492169A 2012-05-22 2013-05-22 Спиропроизводные, представляющие собой 7-метил-2-[4-метил-6-[4-(трифторметил)фенил]пиримидин-2-ил]-1,7-диазаспиро[4,4]нонан-6-он, его применение и композиция, содержащая данное соединение EA025579B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
PCT/GB2013/051335 WO2013175205A1 (en) 2012-05-22 2013-05-22 Novel Compounds

Publications (2)

Publication Number Publication Date
EA201492169A1 true EA201492169A1 (ru) 2015-04-30
EA025579B1 EA025579B1 (ru) 2017-01-30

Family

ID=46546493

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492169A EA025579B1 (ru) 2012-05-22 2013-05-22 Спиропроизводные, представляющие собой 7-метил-2-[4-метил-6-[4-(трифторметил)фенил]пиримидин-2-ил]-1,7-диазаспиро[4,4]нонан-6-он, его применение и композиция, содержащая данное соединение

Country Status (28)

Country Link
US (7) US9376445B2 (ru)
EP (3) EP2861602B1 (ru)
JP (3) JP6169687B2 (ru)
KR (2) KR20200113027A (ru)
CN (2) CN104640867B (ru)
AU (3) AU2013265001B2 (ru)
BR (1) BR112014029280B1 (ru)
CA (1) CA2873956C (ru)
CY (2) CY1118274T1 (ru)
DK (2) DK2861602T3 (ru)
EA (1) EA025579B1 (ru)
ES (3) ES2782088T3 (ru)
GB (1) GB201209015D0 (ru)
HK (1) HK1209423A1 (ru)
HR (2) HRP20161349T1 (ru)
HU (2) HUE031664T2 (ru)
IL (4) IL235805A (ru)
IN (1) IN2014MN02393A (ru)
LT (2) LT2861602T (ru)
MX (1) MX355303B (ru)
PL (2) PL2861602T3 (ru)
PT (2) PT3106464T (ru)
RS (2) RS55415B1 (ru)
SG (2) SG11201407755UA (ru)
SI (2) SI3106464T1 (ru)
SM (1) SMT201600421B (ru)
WO (2) WO2013175206A1 (ru)
ZA (1) ZA201408253B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
MA50669A (fr) * 2017-09-28 2020-08-05 Biogen Inc Nouveaux sels
CA3077088A1 (en) * 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451373T1 (de) * 2002-07-05 2009-12-15 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
ATE472529T1 (de) 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP1934191B1 (en) * 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TW200825091A (en) 2006-10-12 2008-06-16 Xenon Pharmaceuticals Inc Spiro-oxindole compounds useful in treating sodium channel-mediated diseases or conditions
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PL2477964T3 (pl) 2009-09-14 2015-08-31 Convergence Pharmaceuticals Proces wytwarzania pochodnych alfa-karboksyamidu
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
KR20140139000A (ko) * 2012-03-21 2014-12-04 인터디지탈 패튼 홀딩스, 인크 무선 네트워크에서 다른 이동국에 의한 이동국 세션의 스폰서링
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
PL2861602T3 (pl) 2017-05-31
SG11201407755UA (en) 2014-12-30
CN104640867B (zh) 2017-07-21
HUE049445T2 (hu) 2020-09-28
CY1118274T1 (el) 2017-06-28
CN107344942B (zh) 2020-09-25
MX2014014274A (es) 2015-06-17
WO2013175205A1 (en) 2013-11-28
GB201209015D0 (en) 2012-07-04
SMT201600421B (it) 2017-01-10
JP2015517562A (ja) 2015-06-22
JP6169687B2 (ja) 2017-07-26
HK1209423A1 (en) 2016-04-01
EA025579B1 (ru) 2017-01-30
CA2873956A1 (en) 2013-11-28
BR112014029280A2 (pt) 2017-06-27
US20200289508A1 (en) 2020-09-17
IL271330A (en) 2020-01-30
EP2861602A1 (en) 2015-04-22
US20160263115A1 (en) 2016-09-15
HUE031664T2 (en) 2017-07-28
US20180360833A1 (en) 2018-12-20
US20150166551A1 (en) 2015-06-18
ZA201408253B (en) 2015-12-23
PL3106464T3 (pl) 2020-11-16
SI2861602T1 (sl) 2017-03-31
PT2861602T (pt) 2016-11-14
CY1123044T1 (el) 2021-10-29
KR20150023401A (ko) 2015-03-05
JP2017206534A (ja) 2017-11-24
KR102161101B1 (ko) 2020-10-20
HRP20200580T1 (hr) 2020-10-02
IL280595A (en) 2021-03-25
CN107344942A (zh) 2017-11-14
US10010551B2 (en) 2018-07-03
DK2861602T3 (en) 2016-11-28
SG10201703527WA (en) 2017-06-29
ES2782088T3 (es) 2020-09-10
IL271330B (en) 2021-02-28
CN104640867A (zh) 2015-05-20
JP6378404B2 (ja) 2018-08-22
EP2861602B1 (en) 2016-08-10
AU2017201421B2 (en) 2017-12-07
IL252033B (en) 2019-12-31
MX355303B (es) 2018-04-12
LT3106464T (lt) 2020-04-10
EP2861594A1 (en) 2015-04-22
WO2013175206A1 (en) 2013-11-28
US20160184306A1 (en) 2016-06-30
IN2014MN02393A (ru) 2015-08-21
AU2013265001B2 (en) 2016-12-01
US9309254B2 (en) 2016-04-12
US10485801B2 (en) 2019-11-26
IL252033A0 (en) 2017-06-29
US9376445B2 (en) 2016-06-28
LT2861602T (lt) 2016-11-10
RS60368B1 (sr) 2020-07-31
AU2018201653A1 (en) 2018-03-29
EP3106464B1 (en) 2020-01-08
KR20200113027A (ko) 2020-10-05
ES2602308T3 (es) 2017-02-20
JP2015517561A (ja) 2015-06-22
IL235805A (en) 2017-05-29
US20170304303A1 (en) 2017-10-26
BR112014029280B1 (pt) 2022-10-04
RS55415B1 (sr) 2017-04-28
ES2602193T3 (es) 2017-02-20
SI3106464T1 (sl) 2020-12-31
CA2873956C (en) 2021-03-23
EP2861594B1 (en) 2016-08-24
EP3106464A1 (en) 2016-12-21
DK3106464T3 (da) 2020-03-23
PT3106464T (pt) 2020-04-03
IL235805A0 (en) 2015-02-01
AU2018201653B2 (en) 2019-05-02
AU2013265001A1 (en) 2014-12-18
AU2017201421A1 (en) 2017-03-23
US20150119404A1 (en) 2015-04-30
HRP20161349T1 (hr) 2017-01-27
US9737536B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
EA201590868A1 (ru) Противовирусные соединения
EA201790963A1 (ru) Противовирусные соединения
EA201890333A1 (ru) Противовирусные соединения
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201290644A1 (ru) Блокаторы натриевых потенциал-зависимых каналов
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
JO3773B1 (ar) معدلات p2x7
EA201791717A1 (ru) Стабильные водные составы адалимумаба
EA201391106A1 (ru) Новые гетероциклические производные
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
UY33931A (es) Agentes de union biespecificos
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201590887A1 (ru) Композиция
EA201691541A1 (ru) Новые анти-baff антитела
EA201691141A1 (ru) Соединения против ccr6
EA201790570A1 (ru) Модуляторы р2х7
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201492169A1 (ru) Новые соединения
EA201491251A1 (ru) Соединение 2-(пиридин-2-ил)-1,7-диазаспиро[4.4]нонан-6-она в качестве модуляторов потенциалзависимых натриевых каналов